Vicore Pharma is an innovative Swedish clinical-stage pharmaceutical company that focuses on creating life-changing treatments for diseases where the AT2 receptor plays a central role. They have a strong history of collaboration with the scientific community and have gathered preclinical data and ongoing clinical research in multiple indications to prove the AT2 receptor biology. Vicore Pharma is determined to find holistic solutions for patients and their families.

Their flagship product, C21, targets the underlying fibrosis in idiopathic pulmonary fibrosis (IPF) by stimulating the protective arm of the renin-angiotensin system. This leads to alveolar repair, maintenance of alveolar integrity, and a reduction in fibrosis formation, stabilizing the disease and improving lung capacity. Vicore Pharma is also developing other treatments for rare lung diseases such as pulmonary arterial hypertension (PAH) and mental health support for patients with pulmonary fibrosis through their investigational medical device, Almee™.

They are constantly fueling their pipeline with new assets based on their expertise in the ATRAG biology. Vicore Pharma's shares are listed on Nasdaq Stockholm's main market, and they have offices in Stockholm, Sweden, and Hørsholm, Denmark. They are committed to transparency and collaboration, working closely with patient advocacy organizations to understand the patient perspective and develop effective treatments.

If you're interested in joining their team or want to get in touch, visit their website for more information